Financials data is unavailable for this security.
View more
Year on year Catalyst Pharmaceuticals Inc grew revenues 23.49% from 398.20m to 491.73m while net income improved 129.50% from 71.41m to 163.89m.
Gross margin | 86.11% |
---|---|
Net profit margin | 36.91% |
Operating margin | 43.27% |
Return on assets | 25.37% |
---|---|
Return on equity | 29.11% |
Return on investment | 28.93% |
More ▼
Cash flow in USDView more
In 2024, Catalyst Pharmaceuticals Inc increased its cash reserves by 276.03%, or 379.92m. The company earned 239.81m from its operations for a Cash Flow Margin of 48.77%. In addition the company generated 140.67m cash from financing while 556.00k was spent on investing.
Cash flow per share | 1.87 |
---|---|
Price/Cash flow per share | 10.99 |
Book value per share | 6.51 |
---|---|
Tangible book value per share | 5.30 |
More ▼
Balance sheet in USDView more
Current ratio | 6.14 |
---|---|
Quick ratio | 5.96 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 108.95%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years) | 34.26 |
---|---|
EPS (TTM) vs TTM 1 year ago | 191.66 |